Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D) announced today that it has begun to negotiate with both hospital and private HIV clinics as potential sites for the company’s upcoming trial. This comes on the heels of the company’s successful negotiations of a phase I/II protocol with the FDA.
